We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-9.67%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$53.8M
AUM Growth
-$3.73M
(-6.5%)
Cap. Flow
+$2.46M
Cap. Flow
% of AUM
4.58%
Top 10 Holdings %
Top 10 Hldgs %
73.8%
Holding
26
New
6
Increased
8
Reduced
6
Closed
6
Top Buys
| 1 |
HMSY
HMS Holdings Corp.
HMSY
|
+$5.15M |
| 2 |
Quest Diagnostics
DGX
|
+$2.14M |
| 3 |
Eli Lilly
LLY
|
+$1.78M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$1.6M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$1.42M |
Top Sells
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$3.27M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$2.11M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$1.91M |
| 4 |
UnitedHealth
UNH
|
+$1.8M |
| 5 |
Incyte
INCY
|
+$1.67M |
Sector Composition
| 1 | Healthcare | 82.46% |
| 2 | Industrials | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PTC Therapeutics
PTCT
$6.52B
| $5.29M | 9.83% |
484,579
-83,104
| -15% | -$872K |
|
2
Centene
CNC
$32.8B
| $5.06M | 9.41% |
179,138
+43,426
| +32% | +$1.28M |
|
|
HMSY
3
DELISTED
HMS Holdings Corp.
HMSY
| $4.81M | 8.94% |
+264,760
| New | +$5.15M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$15.5B
| $4.64M | 8.64% |
42,597
+14,368
| +51% | +$1.6M |
|
|
5
Eli Lilly
LLY
$1.05T
| $4.19M | 7.79% |
56,984
+23,955
| +73% | +$1.78M |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $3.76M | 6.99% |
756,596
+138,279
| +22% | +$957K |
|
|
SGYP
7
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $3.38M | 6.28% |
555,085
+216,017
| +64% | +$1.13M |
|
|
8
Bio-Rad Laboratories Class A
BIO
$8.15B
| $3.34M | 6.21% |
18,318
-12,369
| -40% | -$2.11M |
|
|
9
Quest Diagnostics
DGX
$23.3B
| $2.71M | 5.04% |
29,485
+24,785
| +527% | +$2.14M |
|
|
10
UnitedHealth
UNH
$387B
| $2.51M | 4.66% |
15,659
-12,069
| -44% | -$1.8M |
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
| $2.43M | 4.51% |
64,095
-86,556
| -57% | -$3.27M |
|
|
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.2M | 4.09% |
166,099
+1,943
| +1% | +$33.2K |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $2.09M | 3.88% |
28,725
+16,564
| +136% | +$1.42M |
|
|
14
Incyte
INCY
$23.4B
| $2.04M | 3.79% |
20,337
-17,070
| -46% | -$1.67M |
|
15
DaVita
DVA
$15.2B
| $1.25M | 2.32% |
+19,451
| New | +$1.21M |
|
16
Edwards Lifesciences
EW
$49.4B
| $956K | 1.78% |
30,600
-11,124
| -27% | -$360K |
|
17
Ironwood Pharmaceuticals
IRWD
$635M
| $877K | 1.63% |
+68,491
| New | +$865K |
|
18
Perrigo
PRGO
$1.48B
| $861K | 1.6% |
+10,339
| New | +$897K |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $703K | 1.31% |
+15,832
| New | +$557K |
|
20
Natera
NTRA
$38.9B
| $694K | 1.29% |
+59,300
| New | +$653K |
|
21
Glaukos
GKOS
$9.21B
| – | – |
-10,233
| Closed | -$386K |
|
|
LKFT
22
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| – | – |
-6,250
| Closed | -$404K |
|
|
23
Neurocrine Biosciences
NBIX
$17.2B
| – | – |
-37,644
| Closed | -$1.91M |
|
24
NovoCure
NVCR
$1.84B
| – | – |
-157,176
| Closed | -$1.34M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2016 Portfolio in Review
As of Q4 2016, Asymmetry Capital Management held 26 positions worth $53.8M, down 6.5% from $57.5M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Asymmetry Capital Management deployed $2.46M of net new capital in Q4 2016, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was HMS Holdings Corp.: 264,760 shares worth $4.81M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $3.27M trimmed.
- Asymmetry Capital Management's largest Q4 2016 buy was HMS Holdings Corp.: 264,760 shares worth $4.81M.
- Asymmetry Capital Management added most to Quest Diagnostics in Q4 2016, an estimated $2.14M increase.
- Asymmetry Capital Management's biggest Q4 2016 reduction was Aerie Pharmaceuticals, cutting an estimated $3.27M.
- Asymmetry Capital Management fully exited Neurocrine Biosciences in Q4 2016, selling an estimated $1.91M.
- Asymmetry Capital Management's ten largest holdings make up 74% of its $53.8M portfolio in Q4 2016.
- Asymmetry Capital Management opened 6 new positions and closed 6 in Q4 2016.
- Asymmetry Capital Management's portfolio value fell 6.5% quarter-over-quarter to $53.8M.
Based on Asymmetry Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.